Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL
CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program targeting BRD9, and how the company thinks about partnerships going forward.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.